New hope for myelofibrosis patients after standard treatments fail
NCT ID NCT04629508
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 23 times
Summary
This study tested a drug called itacitinib in people with myelofibrosis (a serious bone marrow disease) who had already been treated with ruxolitinib or fedratinib. The goal was to see if itacitinib is safe and can shrink an enlarged spleen, a common problem in this condition. Only 4 people took part, and the study is now complete.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
AZ DELTA
Roeselare, 08800, Belgium
-
Aou San Giovanni Di Dio E Ruggi
Salerno, 84131, Italy
-
Baptist Cancer Center
Memphis, Tennessee, 38120, United States
-
Chu Ucl Namur University Hospital Mont-Godinne
Yvoir, 05530, Belgium
-
Cliniques Universitaires Ucl Saint-Luc
Brussels, 01000, Belgium
-
Hospital Universitari I Politecnic La Fe
Valencia, 46000, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Interne 1 - Hematologie Mit Stammzelltransplantation, Hemostaseologie Und Medizinische Onkologie Ord
Linz, 70376, Austria
-
Istituto Di Ricovero E Cura A Carattere Scientifico (Irccs) Ospedale San Raffaele
Milan, 20132, Italy
-
Jessa Ziekenhuis
Hasselt, 03500, Belgium
-
Midamerica Cancer Care
Kansas City, Missouri, 64114, United States
-
New Jersey Hematology Oncology Associates Llc
Brick, New Jersey, 08724-3009, United States
-
Pratia Hematologia Katowice
Katowice, 40-519, Poland
-
Rcca Md, Llc
Bethesda, Maryland, 20817, United States
-
Renovatio Clinical Consultants Llc
Spring, Texas, 77380, United States
-
Texas Oncology - Baylor Sammons Cancer Center
Dallas, Texas, 75246-2092, United States
-
Treviso Hospital
Treviso, 31100, Italy
-
Tulane University
New Orleans, Louisiana, 70112, United States
-
Universitaetsmedizin Greifswald
Greifswald, 17475, Germany
-
Universitatsklinikum Halle (Saale)
Halle, 06120, Germany
-
Vanderbilt University
Nashville, Tennessee, 37235, United States
Conditions
Explore the condition pages connected to this study.